Arcellx CFO Sells 72,000 Shares in Gilead Merger Tender Offer at $115 per Share

*TL;DR – Arcellx CFO Michelle Gilson sold 72,048 shares in a tender offer for $115 per share and a $5 contingent value right (CVR), and converted outstanding RSUs and stock options into cash and CVRs as part of the Gilead Sciences merger.*

Context Arcellx (NASDAQ: ACLX) is being acquired by Gilead Sciences (NASDAQ: GILD). The merger agreement, signed Feb. 22, 2026, makes Arcellx a wholly‑owned subsidiary of Gilead. The transaction triggers cash payouts and CVRs for shareholders who tender shares before the offer expires.

Key Facts - Gilson tendered 5,000 shares held by a family charitable foundation and 67,048 shares held personally, totaling 72,048 shares. Each share fetched $115 in cash and one CVR that may pay an additional $5 per share if merger conditions are met. - All outstanding equity awards were cancelled and converted. The conversion applied to performance‑based and time‑based restricted stock units (RSUs) and to stock options with exercise prices of $8.66, $19.97, $31.03 and $56.15 per share. - For each option whose exercise price was below $115, the holder received cash equal to the excess of $115 over the exercise price, multiplied by the number of options, plus one CVR per option. - Each RSU, whether vested or not, was exchanged for cash equal to $115 per underlying share and one CVR per RSU. - The filing also records a grant of 59,028 performance‑based RSUs. Each RSU gives the holder a right to one Arcellx share under the merger terms, effectively adding the same number of CVRs to the pool.

What It Means The cash component of $115 per share represents a premium to Arcellx’s pre‑announcement trading range, providing immediate liquidity to the CFO and other insiders. The CVR adds a contingent upside tied to post‑merger performance metrics, aligning insider interests with Gilead’s integration success. Conversion of low‑priced options into cash eliminates any residual dilution risk for Gilead while rewarding option holders for the premium price. The new RSU grant expands the pool of CVRs, potentially increasing future cash outflows if the merger’s performance targets are met. Arcellx’s market cap, calculated on the $115 cash price, exceeds $8 billion, positioning the combined entity as a significant player in the biotech sector. Investors will watch Gilead’s integration plan and the conditions governing the $5 CVR payouts.

Looking Ahead Monitor Gilead’s filing of the CVR agreement and any updates on performance milestones that could trigger the additional $5 per CVR, as these will affect the final cash distribution to former Arcellx shareholders.